Avoro Capital Advisors LLC - Nov 22, 2021 Form 4 Insider Report for CymaBay Therapeutics, Inc. (CBAY)

Role
10%+ Owner
Signature
Avoro Capital Advisors LLC, by: /s/ Scott Epstein, its Chief Financial Officer & Chief Compliance Officer
Stock symbol
CBAY
Transactions as of
Nov 22, 2021
Transactions value $
$9,999,750
Form type
4
Date filed
11/23/2021, 03:15 PM
Next filing
Jan 30, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CBAY Pre-funded Warrant (right to buy) Purchase $10M +2.5M $4.00 2.5M Nov 22, 2021 Common Stock 2.5M $0.00 See footnotes F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Subject to the terms and conditions set forth in the Pre-funded Warrant, the holder thereof may, at any time and from time to time on or after November 22, 2021, exercise the Pre-funded Warrant until it has been exercised in full.
F2 The securities reported herein are held on behalf of accounts managed by Avoro Capital Advisors LLC, a Delaware limited liability company (the "Investment Manager") and Avoro Life Sciences Fund LLC, a Delaware limited liability company, a fund managed by the Investment Manager. Behzad Aghazadeh ("Dr. Aghazadeh," and together with the Investment Manager, the "Reporting Persons") serves as the portfolio manager and controlling person of the Investment Manager.
F3 The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.